<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93025">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893879</url>
  </required_header>
  <id_info>
    <org_study_id>BRSNSTU0028</org_study_id>
    <nct_id>NCT01893879</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema</brief_title>
  <acronym>PCTTPL</acronym>
  <official_title>Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies an investigational drug in preventing lymphedema in
      patients at high risk after undergoing axillary lymph node dissection. The study drug may
      prevent lymphedema in patients undergoing axillary lymph node dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the efficacy of study drug in improving chronic lymphedema while further
      elucidating the role of inflammatory and lymphangiogenic processes in the pathogenesis of
      this disease.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive study drug orally (PO) thrice daily (TID) for up to 1 year in the
      absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO TID for up to 1 year in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of lymphedema and/or severity of lymphedema</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Lymphedema</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>(RS)2-(3-benzoylphenyl)-propionic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
Laboratory biomarker analysis will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo for study drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
Laboratory biomarker analysis will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for study drug</intervention_name>
    <description>Given PO</description>
    <arm_group_label>placebo for study drug</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(RS)2-(3-benzoylphenyl)-propionic acid</intervention_name>
    <description>Given PO</description>
    <arm_group_label>(RS)2-(3-benzoylphenyl)-propionic acid</arm_group_label>
    <other_name>BPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>(RS)2-(3-benzoylphenyl)-propionic acid</arm_group_label>
    <arm_group_label>placebo for study drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Axillary lymph node dissection within the preceding 12 months

        Exclusion Criteria:

          -  Patients with active cancer

          -  Patients with lymphedema

          -  Infection or bleeding tendency

          -  Patients with medical contraindications to nonsteroidal anti-inflammatory drugs
             (NSAIDs), including history of allergies, know gastrointestinal intolerance

          -  Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive
             heart failure, neurological or psychological impairment) that would impair the
             patients' ability to participate

          -  Persons not competent to consent

          -  Patients on aspirin therapy

          -  Minors (&lt; 18 years of age)

          -  Pregnant and/or lactating women

          -  Males
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Rockson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 13, 2016</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Stanley Rockson</investigator_full_name>
    <investigator_title>Allan and Tina Neill Professor of Lymphatic Research and Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
